About inventiva sa - IVA
Inventiva SA is a clinical-stage biopharmaceutical company, which focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis, or NASH, and other diseases with significant unmet medical need. It owns an in-house drug-discovery platform that develops internal oncology and fibrosis discovery pipeline with approaches centered on transcription factors, epigenetics targets, and nuclear receptors. The company was founded by Pierre Broqua and Frédéric Cren on October 27, 2011 and is headquartered in Daix, France.
IVA At a Glance
Inventiva SA
50, rue de Dijon
Daix, Bourgogne-Franche-Comte 21121
| Phone | 33-3-80-44-75-00 | Revenue | 9.95M | |
| Industry | Biotechnology | Net Income | -199,260,417.60 | |
| Sector | Health Technology | Employees | 119 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
IVA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 12.858 |
| Price to Book Ratio | N/A |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.811 |
| Enterprise Value to Sales | 8.454 |
| Total Debt to Enterprise Value | 0.668 |
IVA Efficiency
| Revenue/Employee | 83,608.333 |
| Income Per Employee | -1,674,457.291 |
| Receivables Turnover | 0.79 |
| Total Asset Turnover | 0.10 |
IVA Liquidity
| Current Ratio | 0.921 |
| Quick Ratio | 0.921 |
| Cash Ratio | 0.80 |
IVA Profitability
| Gross Margin | 60.992 |
| Operating Margin | -1,081.485 |
| Pretax Margin | -2,049.076 |
| Net Margin | -2,002.74 |
| Return on Assets | -200.056 |
| Return on Equity | N/A |
| Return on Total Capital | 364.864 |
| Return on Invested Capital | N/A |
IVA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | -102.873 |
| Total Debt to Total Assets | 45.739 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | -91.885 |